VPB0118 - Proper algorithm in donor-recipient selection, the key to success in convalescent plasma treatment of Covid 19 patients

Background: Convalescent plasma (CP) obtained from patients following recovery from COVID-19 is an option for treatment, since antibodies may have antiviral and anticoagulation effect.

Aims: The goal of this review is to present the latest evidence in the use of CP for COVID-19, raise questions regarding donor selection, collection, testing of CP, timing and volume of CP, and offer recommendations for future research.

Methods: -Systematic review of all published available literature assessing the use of CP for COVID-19.
-Simple scoring was structured (0 min-10max). Minimal score (O) gives maximal possibility of successfully treatment with CP in COVID-19 patients and the opposite. This scoring system was applied into chosen 54 published studies.

Results: We analyzed data in 18 published Case reports, 31 Case series, 11 Observational studies, and 5 RTc .According to our score min.score 0 was not obtained in any type of study, either score 1 or 2. Only one observational study has score 3 . In this group score vary from 3 to 9,5, but most studies had a high score (6 -9). In the group of case reports score was from 4 to 8 (the largest number had a score of 7). In case report studies the score vary from 4 (just one case) to 8. Higher scores were registered in the largest number of case reports also. In the case series that were the most numerous (31) available reports concerning research in CP treatment of COVID 9 patients, the minimum score was 5 (only one series), the max score was 10, and most series had a score of 6 to 9. The number of randomized studies was the lowest, only 5. In this group, the score ranged from 6.5 -9.

Conclusion(s): Despite a number of performed studies there is not god enough pretreatment estimation for success of CP treatment in COVID .